2019
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation
Pokorney SD, Holmes DN, Shrader P, Thomas L, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Naccarelli GV, Freeman JV, Singer DE, Washam JB, Peterson ED, Piccini JP, Reiffel JA. Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. American Heart Journal 2019, 220: 145-154. PMID: 31812756, DOI: 10.1016/j.ahj.2019.09.017.Peer-Reviewed Original ResearchConceptsUse of amiodaroneAmiodarone useAntiarrhythmic drugsAtrial fibrillationAF patientsDifferent antiarrhythmic drugsGuideline-based indicationsPropensity-matched cohortEffective antiarrhythmic drugProportional hazard modelingORBIT-AF registryLogistic regression modelsHierarchical logistic regressionCause mortalityAF RegistryCardiovascular hospitalizationAmiodaroneHigh incidencePatientsClinical practiceHazard modelingLogistic regressionAdverse effectsRandom interceptFibrillation
2007
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality
Thomas KL, Al-Khatib SM, Lokhnygina Y, Solomon SD, Kober L, McMurray JJ, Califf RM, Velazquez EJ. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. American Heart Journal 2007, 155: 87-93. PMID: 18082495, DOI: 10.1016/j.ahj.2007.09.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmiodaroneCaptoprilCause of DeathDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionProbabilityProportional Hazards ModelsReference ValuesRisk AssessmentSeverity of Illness IndexSurvival AnalysisTetrazolesTreatment OutcomeValineValsartanVentricular DysfunctionConceptsVentricular systolic dysfunctionAmiodarone useAcute myocardial infarctionMyocardial infarctionSystolic dysfunctionLeft ventricular systolic dysfunctionPost-acute myocardial infarctionHazard ratio 1.5Higher Killip classTrials of amiodaroneKillip classVentricular dysfunctionBaseline characteristicsCardiovascular mortalityDiabetes mellitusHeart failureMedical regimenRandomized comparisonBaseline predictorsExcess mortalityCox modelSubsequent mortalityDay 1PatientsAmiodarone
2000
Granular Cells as a Marker of Early Amiodarone Hepatotoxicity
Jain D, Bowlus C, Anderson J, Robert M. Granular Cells as a Marker of Early Amiodarone Hepatotoxicity. Journal Of Clinical Gastroenterology 2000, 31: 241-243. PMID: 11034006, DOI: 10.1097/00004836-200010000-00012.Peer-Reviewed Original ResearchConceptsChronic amiodarone useGranular cellsAmiodarone useAcute hepatitisAcute administrationLiver biopsyPathologic findingsIdiosyncratic reactionsAD therapyAmiodarone hepatotoxicityGranular cytoplasmHepatotoxicityClusters of cellsHepatitisMembranous inclusionsCellsBiopsyHistologicTherapyCliniciansLiverMacrophagesAdministrationWeeks
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply